Verastem | VSTM - Selling And Administration Expenses

Stock Price
6.09
Daily Change
-0.44 -6.67%
Monthly
12.89%
Yearly
-13.57%
Q2 Forecast
6.44

Verastem reported $24.44M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Alaunos Therapeutics USD 585K 84K Sep/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Curis USD 1.34M 3.45M Dec/2025
Cytokinetics USD 91.72M 67.02M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Laboratory Of America USD 538.6M 13.8M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
TG Therapeutics USD 50.73M 12.64M Dec/2025
Verastem USD 24.44M 12.17M Dec/2025